In the latest trading session, 1.54 million Ocugen Inc (NASDAQ:OCGN) shares changed hands as the company’s beta touched 3.89. With the company’s most recent per share price at $0.61 changed hands at -$0.02 or -3.60% at last look, the market valuation stands at $176.70M. OCGN’s current price is a discount, trading about -245.9% off its 52-week high of $2.11. The share price had its 52-week low at $0.63, which suggests the last value was -3.28% down since then.
Analysts gave the Ocugen Inc (OCGN) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended OCGN as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight.
Ocugen Inc (NASDAQ:OCGN) trade information
Instantly OCGN was in red as seen in intraday trades today. With action -16.69%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -24.56%, with the 5-day performance at -16.69% in the red. However, in the 30-day time frame, Ocugen Inc (NASDAQ:OCGN) is -22.14% down.
The consensus price target for the stock as assigned by Wall Street analysts is 5, meaning bulls need an upside of 87.8% from its recent market value. According to analyst projections, OCGN’s forecast low is 3.5 with 6 as the target high. To hit the forecast high, the stock’s price needs a -883.61% plunge from its current level, while the stock would need to soar -473.77% for it to hit the projected low.
Ocugen Inc (OCGN) estimates and forecasts
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 41.20%. The 2025 estimates are for Ocugen Inc earnings to increase by 23.08%, but the outlook for the next 5-year period is at 4.71% per year.
Ocugen Inc (NASDAQ:OCGN)’s Major holders
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 6.0339% or 15.52 million shares worth $24.06 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF. With 9.07 shares estimated at $5.56 million under it, the former controlled 3.11% of total outstanding shares. On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF held about 2.99% of the shares, roughly 8.7 shares worth around $5.33 million.
